- Home
- LIDR vs MREO Comparison
LIDR vs MREO Comparison
Compare LIDR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIDR | MREO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | 56 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 49.4M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LIDR | MREO |
|---|---|---|
| Price | $1.41 | $0.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $4.75 | $1.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $2,604.29 | $5,184.20 |
| Revenue Next Year | $466.58 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.20 |
| 52 Week High | $6.44 | $2.37 |
Technical Indicators
Market Signals| Indicator | LIDR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 59.07 |
| Support Level | $1.37 | $0.30 |
| Resistance Level | $1.77 | $0.36 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 37.04 | 84.09 |
Price Performance
Historical ComparisonAbout LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).